Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities  

作　　者：Aditi Jain Vikas Bhardwaj 

机构地区：[1]The Jefferson Pancreas,Biliary and Related Cancer Center,Department of Surgery,Sidney Kimmel Cancer Center,Thomas Jefferson University,Philadelphia,PA 19107,United States [2]Department of Pharmaceutical Sciences,Jefferson College of Pharmacy,Thomas Jefferson University,Philadelphia,PA 19107,United States

出　　处：《World Journal of Gastroenterology》2021年第39期6527-6550,共24页世界胃肠病学杂志（英文版）

摘　　要：Pancreatic ductal adenocarcinoma(PDAC)is the third leading cause of cancerrelated deaths in the United States.Although chemotherapeutic regimens such as gemcitabine+nab-paclitaxel and FOLFIRINOX(FOLinic acid,5-Fluroruracil,IRINotecan,and Oxaliplatin)significantly improve patient survival,the prevalence of therapy resistance remains a major roadblock in the success of these agents.This review discusses the molecular mechanisms that play a crucial role in PDAC therapy resistance and how a better understanding of these mechanisms has shaped clinical trials for pancreatic cancer chemotherapy.Specifically,we have discussed the metabolic alterations and DNA repair mechanisms observed in PDAC and current approaches in targeting these mechanisms.Our discussion also includes the lessons learned following the failure of immunotherapy in PDAC and current approaches underway to improve tumor’s immunological response.

关 键 词：Pancreatic cancer METABOLISM DNA repair Therapy-resistance IMMUNOTHERAPY 

分 类 号：R735.9[医药卫生—肿瘤]